Azepine derivatives of the general Formula I <FORM:1038914/C2/1> wherein X and Y independently of each other represent hydrogen or chlorine atoms, Z represents hydrogen or a low alkanoyl radical, R1 represents hydrogen or a methyl radical, R2 represents a low alkyl radical, and R3 represents hydrogen or a low alkyl radical, or R2 and R3 together with the adjacent nitrogen atom, with or without an oxygen atom or with another nitrogen atom form a heterocyclic ring; the term "low" means that the alkyl group in the radicals concerned contain from 1-4 carbon atoms, and water soluble salts of the compounds above with a pharmaceutically acceptable acid are made by reacting a compound of the general Formula II <FORM:1038914/C2/2> wherein Z1 represents a low alkanoyl radical of at most 4 carbon atoms, X, Y and R1 have the meaning given before, with at least an equimolar amount of anamine of the general Formula IV <FORM:1038914/C2/3> wherein R2 and R3 have the above meanings, until the bromine atom is replaced, isolating the compound so obtained and, if desired, hydrolysing it in order to split off the low alkanoyl radical Z1, and, if desired, transforming the azepinamine so obtained of the general Formula I into an acid addition salt with an inorganic or an organic acid. Preferred is that the radical Z1 is the acetyl radical and the amine of Formula IV is dimethylamine. The products and their salts with inorganic and organic acid are stated to have sedative, anaesthesia potentiating, anti-convulsive and histamine-antagonistic action, and may be administered orally, for example as neuroleptics and psycho-sedatives, or in the form of aqueous solutions of their salts, also parenterally. They are stated to be suitable in combinations with other psychopharmaceuticals in particular with anti-depressives. Starting materials of the general Formula II may be obtained from the 10-methyl-and 10-ethyl-5H-debenz(b.f.) azepines carrying the defined substituents X and Y by alkanoylation, for example, with an acyl chloride and the acylated product is brominated by means of an allylic bromination agent for example bromosuccinimide. The examples to illustrate the following synthetic stages: 10-methyl-5H-dibenz(b,f) azepine is reacted with acetyl chloride to give 5-acetyl-10-methyl-5H-dibenz(b,f) azepine, this is then treated with bromosuccinimide to give 10-bromomethyl-5-acetyl-5H-dibenz(b,f) azepine and this in turn is reacted with dimethylamine to give 10-dimethylamino-methyl-5-acetyl-5H-dibenz(b,f) azepine. Hydrolysis of this product with ethanolic caustic potash yields 10-dimethylaminomethyl-5H-dibenz(b,f) azepine. Analogously the following are obtained: 10 - methylaminomethyl - 5H - dibenz(b,f) azepine; 10 - piperidinomethyl - 5H - dibenz(b,f) azepine hydrochloride; 10 - (11-pyrrolidinylmethyl)-5H-dibenz(b,f)azepine; 10-diethylaminomethyl-5H-dibenz(b,f)azepine; 10-(41-(beta-hydroxyethyl)-11-piperazinylmethyl)-5H - dibenz(b,f) azepine fumarate; 10 - (41-methyl-11-piperazinylmethyl) - 5H - dibenz(b,f)-azepine dihydrochloride; 5-acetyl-10-(alpha-bromomethyl) -5H-dibenz(b,f)azepine; 10-alpha-(41-(beta-hydroxyethyl)-11-piperazinyl) -ethyl-5H-dibenz(b,f) azepine; ethyl)-5H-dibenz(b,f) azepine; 10-(alpha-(11-pyrrolidinyl)-ethyl)-5H-dibenz(b,f)azepine; 10-(alpha-dimethylamino-ethyl)-5H-dibenz(b,f) azepine; 10-(alpha-diethylamino-ethyl)-5H-dibenz(b,f)azepine; 10-(alpha-methylamino-ethyl)-5H-dibenz(b,f) azepine. The following two compounds are obtained in an analogous manner starting from 5-acetyl-3,7 - dichloro - 10 - methyl - 5H - dibenz(b,f) azepine by way of 5-acetyl-10-bromomethyl-3,7-dichloro - 5H - dibenz(b,f) azepine, for example: 3,7 - dichloro - 10 - dimethylaminomethyl - 5H - dibenz(b,f) azepine, and 3,7 - dichloro - 10 - (41-(beta - hydroxyethyl) - 11 - piperazinylmethyl)-5H-dibenz(b,f) azepine. In another example 3 - chloro - 5 - acetyl - 5H - dibenz(b,f) azepine is treated with bromine to yield 3-chloro-5-acetyl - 10,11 - dibromo - 10,11 - dihydro - 5H - dibenz(b,f) azepine, which on treatment with alcoholic potassium hydroxide yields the two isomers namely the 10-bromo and the 11-bromo compound. The 11-bromo compound is then reacted with sodium methylate to give the 11-methoxy compound. The 10-bromo compound is converted analogously to the 10-methoxy compound. The 10-methoxy compound is then reacted with sodium amide and benzyl chloride to yield 3 - chloro - 5 - benzyl - 10 - methoxy-5H-dibenz(b,f) azepine, the 11-methoxy being obtained in the analogous manner. On hydrolysis with hydrochloric acid 3-chloro-5-benzyl-5H - dibenz(b,f) azepine - 10(11H) - one is obtained. The 11-methoxy isomer analogously yields the isomeric product. The ketones thus obtained are reacted with methyl magnesium iodide by a Grignard reaction to yield 3-chloro-5-benzyl - 11 - methyl - 11 - hydroxy - 10,11 - dihydro-5H-dibenz(b,f) azepine and this on hydrolysis gives 3-chloro-5-benzyl-11-methyl-5H-dibenz(b,f) azepine. The 10-methyl isomer is obtained analogously. Debenzylation is carried out by heating in benzyl alcohol with hydrobromic acid to give 3-chloro-11-methyl-5H-dibenz(b,f) azepine and 3-chloro-10-methyl-5H-dibenz(b,f) azepine respectively. These products are then acetylated as before, alylic brominated to give 3-chloro-5-acetyl-11-bromomethyl - 5H - dibenz(b,f) azepine and 3-chloro-5 - acetyl - 10 - bromomethyl - 5H - dibenz(b,f)azepine and these are, then reacted with dimethylamine to give the corresponding 11- and 10-dimethyl aminomethyl compounds. These may then be hydrolysed with ethanolic caustic potash to remove the acetyl group from position 5. By substituting methylamine the monomethylamino compounds are obtained. 10-Dimethylaminomethyl - 5H - dibenz(b,f azepine on treatment with ethyl chloroformate affords 10-(N-ethoxy-carbonyl-methylaminomethyl)-5H-dibenz(b,f) azepine which on hydrolysis with caustic potash finally gives 10-methyl-aminomethyl-5H-dibenz(b,f) azepine.